SRC and glioblastoma: A new SRC inhibitor, belonging to the pyrazolo[3 ̈ -d] pyrimidines series (i.e., Si306, Lead Discovery Siena, Italy) showed an excellent pharmacodynamic profile and was able to significantly inhibit GBM cell growth in highly P-gp expressing cells as compared to dasatinib [116].